Fig. 3: Landmark analysis according to BCR::ABL1 transcript level (≤10% vs. >10%) at three months.

A Cumulative incidence of MMR. B Cumulative incidence of on-treatment progression/death (EFS). CI confidence interval, EFS event-free survival, HR hazard ratio, MMR major molecular response.